Related references
Note: Only part of the references are listed.Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody
Theo Rispens et al.
ANALYTICAL BIOCHEMISTRY (2011)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options
Peter Wipfler et al.
DRUG DISCOVERY TODAY (2011)
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells
Andrea Harrer et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients
Mario Skarica et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis
J. Kraus et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Natalizumab treatment reduces endothelial activity in MS patients
Alban Millonig et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford et al.
LANCET NEUROLOGY (2010)
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment
P Wipfler et al.
Multiple Sclerosis Journal (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)
D. B. Clifford et al.
LANCET NEUROLOGY (2010)
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Maria del Pilar Martin et al.
ARCHIVES OF NEUROLOGY (2008)
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
Fabian Zohren et al.
BLOOD (2008)
Antigen-specific therapies in MS - Current concepts and novel approaches
Andreas Lutterotti et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
M. Krumbholz et al.
NEUROLOGY (2008)
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells
L. Airas et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL
P. A. Calabresi et al.
NEUROLOGY (2007)
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta
M. Saraste et al.
NEUROLOGICAL SCIENCES (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
Olaf Stuve et al.
ARCHIVES OF NEUROLOGY (2006)
The impact of interferon-β treatment on the blood-brain barrier
Joerg Kraus et al.
DRUG DISCOVERY TODAY (2006)
Natalizumab effects on immune cell responses in multiple sclerosis
M Niino et al.
ANNALS OF NEUROLOGY (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Early development of therapeutic biologics - Pharmacokinetics
A Baumann
CURRENT DRUG METABOLISM (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis
O Stüve et al.
ARCHIVES OF NEUROLOGY (2005)
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS
MJ Eikelenboom et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
IFN-α subtypes differentially affect human T cell motility
GR Foster et al.
JOURNAL OF IMMUNOLOGY (2004)
Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity
LF Kastrukoff et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Differential expression of beta 1 and beta 2 integrins and L-selectin on CD4(+) and CD8(+) T lymphocytes in human blood: comparative analysis between isolated cells, whole blood samples and cryopreserved preparations
M Cavers et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Human natural killer cells:: a unique innate immunoregulatory role for the CD56bright subset
MA Cooper et al.
BLOOD (2001)
Share Paper
